This content is restricted.
Brief
On "15/07/2025", the "Medicines and Healthcare products Regulatory Agency (MHRA)" issued an update regarding "MHRA approves sebetralstat (Ekterly) to treat hereditary angioedema (HAE) attacks in patients aged 12 and over". This approval marks the first oral, on-demand treatment for HAE and provides patients with a new option to manage attacks quickly and effectively. Sebetralstat works by blocking bradykinin, preventing swelling and pain associated with HAE attacks.
Highlights content goes here...
This content is restricted.
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
